Epicutaneous allergen immunotherapy induces a profound and selective modulation in skin dendritic-cell subsets
Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Epicutaneous immunotherapy (EPIT) protocols have recently been developed to restore tolerance in patients with food allergy. The mechanisms by which EPIT protocols promote desensitization rely on a profound immune deviation of pathogenic T- and B-cell responses.
OBJECTIVE: To date, little is known about the contribution of skin dendritic cells (skDCs) to T-cell remodeling and EPIT efficacy.
METHODS: We capitalized on a preclinical model of food allergy to ovalbumin (OVA) to characterize the phenotype and functions of OVA+ skDCs throughout the course of EPIT.
RESULTS: Our results showed that both Langerhans cells and dermal conventional cDC1 and cDC2 subsets retained their ability to capture OVA in the skin and to migrate toward the skin-draining lymph nodes during EPIT. However, their activation/maturation status was significantly impaired, as evidenced by the gradual and selective reduction of CD86, CD40, and OVA protein expression in respective subsets. Phenotypic changes during EPIT were also characterized by a progressive diversification of single-cell gene signatures within each DC subset. Interestingly, we observed that OVA+ Langerhans cells progressively lost their capacity to prime CD4+ TEFF cells, but gained regulatory T-cell stimulatory properties. In contrast, cDC1 were inefficient in priming CD4+ TEFF cells or in reactivating TMEM cells in vitro, whereas cDC2 retained moderate stimulatory properties, and progressively biased type 2 immunity toward type 1 and type 17 responses.
CONCLUSIONS: Our results therefore emphasize that the acquisition of distinct phenotypic and functional specializations by skDCs during EPIT is at the cornerstone of the desensitization process.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:150 |
|---|---|
| Enthalten in: |
The Journal of allergy and clinical immunology - 150(2022), 5 vom: 01. Nov., Seite 1194-1208 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Laoubi, Léo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9006-59-1 |
|---|
| Anmerkungen: |
Date Completed 08.11.2022 Date Revised 22.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaci.2022.05.025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343004186 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343004186 | ||
| 003 | DE-627 | ||
| 005 | 20231226015417.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaci.2022.05.025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1143.xml |
| 035 | |a (DE-627)NLM343004186 | ||
| 035 | |a (NLM)35779666 | ||
| 035 | |a (PII)S0091-6749(22)00884-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Laoubi, Léo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Epicutaneous allergen immunotherapy induces a profound and selective modulation in skin dendritic-cell subsets |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2022 | ||
| 500 | |a Date Revised 22.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Epicutaneous immunotherapy (EPIT) protocols have recently been developed to restore tolerance in patients with food allergy. The mechanisms by which EPIT protocols promote desensitization rely on a profound immune deviation of pathogenic T- and B-cell responses | ||
| 520 | |a OBJECTIVE: To date, little is known about the contribution of skin dendritic cells (skDCs) to T-cell remodeling and EPIT efficacy | ||
| 520 | |a METHODS: We capitalized on a preclinical model of food allergy to ovalbumin (OVA) to characterize the phenotype and functions of OVA+ skDCs throughout the course of EPIT | ||
| 520 | |a RESULTS: Our results showed that both Langerhans cells and dermal conventional cDC1 and cDC2 subsets retained their ability to capture OVA in the skin and to migrate toward the skin-draining lymph nodes during EPIT. However, their activation/maturation status was significantly impaired, as evidenced by the gradual and selective reduction of CD86, CD40, and OVA protein expression in respective subsets. Phenotypic changes during EPIT were also characterized by a progressive diversification of single-cell gene signatures within each DC subset. Interestingly, we observed that OVA+ Langerhans cells progressively lost their capacity to prime CD4+ TEFF cells, but gained regulatory T-cell stimulatory properties. In contrast, cDC1 were inefficient in priming CD4+ TEFF cells or in reactivating TMEM cells in vitro, whereas cDC2 retained moderate stimulatory properties, and progressively biased type 2 immunity toward type 1 and type 17 responses | ||
| 520 | |a CONCLUSIONS: Our results therefore emphasize that the acquisition of distinct phenotypic and functional specializations by skDCs during EPIT is at the cornerstone of the desensitization process | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Food allergy | |
| 650 | 4 | |a T-cell responses | |
| 650 | 4 | |a allergen immunotherapy | |
| 650 | 4 | |a desensitization | |
| 650 | 4 | |a epicutaneous immunotherapy | |
| 650 | 4 | |a skin dendritic cells | |
| 650 | 7 | |a Ovalbumin |2 NLM | |
| 650 | 7 | |a 9006-59-1 |2 NLM | |
| 650 | 7 | |a Allergens |2 NLM | |
| 700 | 1 | |a Lacoffrette, Morgane |e verfasserin |4 aut | |
| 700 | 1 | |a Valsesia, Séverine |e verfasserin |4 aut | |
| 700 | 1 | |a Lenief, Vanina |e verfasserin |4 aut | |
| 700 | 1 | |a Guironnet-Paquet, Aurélie |e verfasserin |4 aut | |
| 700 | 1 | |a Mosnier, Amandine |e verfasserin |4 aut | |
| 700 | 1 | |a Dubois, Gwendoline |e verfasserin |4 aut | |
| 700 | 1 | |a Cartier, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Monti, Laurine |e verfasserin |4 aut | |
| 700 | 1 | |a Marvel, Jacqueline |e verfasserin |4 aut | |
| 700 | 1 | |a Espinosa, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Malissen, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Henri, Sandrine |e verfasserin |4 aut | |
| 700 | 1 | |a Mondoulet, Lucie |e verfasserin |4 aut | |
| 700 | 1 | |a Sampson, Hugh A |e verfasserin |4 aut | |
| 700 | 1 | |a Nosbaum, Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolas, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Dioszeghy, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Vocanson, Marc |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of allergy and clinical immunology |d 1971 |g 150(2022), 5 vom: 01. Nov., Seite 1194-1208 |w (DE-627)NLM000018449 |x 1097-6825 |7 nnns |
| 773 | 1 | 8 | |g volume:150 |g year:2022 |g number:5 |g day:01 |g month:11 |g pages:1194-1208 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaci.2022.05.025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 150 |j 2022 |e 5 |b 01 |c 11 |h 1194-1208 | ||